{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-134386","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.772550+00:00","generated_at":"2026-06-16T01:09:00.238253+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Reneo Pharma reports $93.8M cash; enters non-binding term sheet for up to $100M royalty financing","bullets":["Preliminary cash, cash equivalents and short-term investments of $93.8M as of March 31, 2023.","Non-binding term sheet for structured royalty financing up to $100M with an insider investor (>5% holder).","Initial $30M at closing, additional tranches based on milestones; deal expected Q2 2023 if definitive.","Collaboration agreement with affiliate development company; joint steering committee planned.","Mavodelpar (REN001) royalty payments would apply if approved in US or EU."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-134386","json":"https://secwatch.observer/filing/0001193125-23-134386.json","markdown":"https://secwatch.observer/filing/0001193125-23-134386.md","text":"https://secwatch.observer/filing/0001193125-23-134386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000119312523134386/0001193125-23-134386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000119312523134386/d133319d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T01:09:00.238253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}